argenx SE Stock: price and insider trades · Netherlands

Every trade that managers of argenx SE disclose to AFM is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Amsterdam, Belgium. It was founded in 2008. Its latest reported headcount is 1,863 employees (2025). From 18 October 2025 to 18 October 2026, the disclosure feed for argenx SE logged 129 filings by 31 insiders.

The record shows 3 purchases on the open market, made by 3 insiders, against 41 sales worth €131.5M by 16 insiders. The amount is not disclosed for 3 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a sale of €26.7M from Lemmen A., disclosed on 10 September 2026. The buyers include 3 senior executives.

The clock since the last published purchase (19 September 2026) now reads 29 days. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

For context, the typical company on the same exchange (median of 126 companies) published 7 filings over the same period, against 129 filings here. Looking back to 2014, when coverage begins, insiders filed 70 purchases and 95 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from AFM disclosures alone and does not predict where the share price will go.